Rhythm Pharmaceuticals (RYTM) announced the FDA has accepted the company's supplemental New Drug Application for IMCIVREE, a melanocortin-4 receptor agonist, for the treatment of obesity due to Bardet-Biedl syndrome or pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency obesity in children as young as 2 years old. The FDA has granted Priority Review of the sNDA and assigned a PDUFA goal date of December 26, 2024.
In the U.S., IMCIVREE is currently indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.